David Haas
Last active: 3/20/2015


My research focuses on understanding the importance of human genomics for pharmacokinetics, efficacy, and toxicity of anti-infective medications. Since 2000 I have led the pharmacogenomics program of the NIAID-funded AIDS Clinical Trials Group (ACTG), and led the effort to establish the ACTG Human DNA Repository. I have designed pharmacogenomics analyses across many clinical trials, observational cohorts, and other databases. Since 1994, I have directed Vanderbilt’s HIV Therapeutics Clinical Research Program. My work led to the seminal observation that a CYP2B6 variant predicts delayed clearance of efavirenz, which largely explains increased plasma exposure among individuals of African descent, and may help predict CNS side effects and virologic response.


The following timeline graph is generated from all co-authored publications.

Featured publications are shown below:

  1. Phase I safety, pharmacokinetics, and pharmacogenetics study of the antituberculosis drug PA-824 with concomitant lopinavir-ritonavir, efavirenz, or rifampin. Dooley KE, Luetkemeyer AF, Park JG, Allen R, Cramer Y, Murray S, Sutherland D, Aweeka F, Koletar SL, Marzan F, Bao J, Savic R, Haas DW, AIDS Clinical Trials Group A5306 Study Team (2014) Antimicrob Agents Chemother 58(9): 5245-52
    › Primary publication · 24957823 (PubMed) · PMC4135849 (PubMed Central)
  2. Secondary metabolism pathway polymorphisms and plasma efavirenz concentrations in HIV-infected adults with CYP2B6 slow metabolizer genotypes. Haas DW, Kwara A, Richardson DM, Baker P, Papageorgiou I, Acosta EP, Morse GD, Court MH (2014) J Antimicrob Chemother 69(8): 2175-82
    › Primary publication · 24729586 (PubMed) · PMC4100708 (PubMed Central)
  3. Genomewide association study of atazanavir pharmacokinetics and hyperbilirubinemia in AIDS Clinical Trials Group protocol A5202. Johnson DH, Venuto C, Ritchie MD, Morse GD, Daar ES, McLaren PJ, Haas DW (2014) Pharmacogenet Genomics 24(4): 195-203
    › Primary publication · 24557078 (PubMed) · PMC4059003 (PubMed Central)
  4. Genetic and non-genetic determinants of raltegravir penetration into cerebrospinal fluid: a single arm pharmacokinetic study. Johnson DH, Sutherland D, Acosta EP, Erdem H, Richardson D, Haas DW (2013) PLoS One 8(12): e82672
    › Primary publication · 24349334 (PubMed) · PMC3859605 (PubMed Central)
  5. Clinical and genetic determinants of plasma nevirapine exposure following an intrapartum dose to prevent mother-to-child HIV transmission. Vardhanabhuti S, Acosta EP, Ribaudo HJ, Severe P, Lalloo U, Kumarasamy N, Taulo F, Kabanda J, Oneko O, Ive P, Sambarey P, Chan ES, Hitti J, Hong F, McMahon D, Haas DW, A5207 ACTG Study Team (2013) J Infect Dis 208(4): 662-71
    › Primary publication · 23687222 (PubMed) · PMC3719905 (PubMed Central)
  6. Impact of UGT1A1 Gilbert variant on discontinuation of ritonavir-boosted atazanavir in AIDS Clinical Trials Group Study A5202. Ribaudo HJ, Daar ES, Tierney C, Morse GD, Mollan K, Sax PE, Fischl MA, Collier AC, Haas DW, DS Clinical Trials Group (2013) J Infect Dis 207(3): 420-5
    › Primary publication · 23148286 (PubMed) · PMC3537445 (PubMed Central)
  7. Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variants. Holzinger ER, Grady B, Ritchie MD, Ribaudo HJ, Acosta EP, Morse GD, Gulick RM, Robbins GK, Clifford DB, Daar ES, McLaren P, Haas DW (2012) Pharmacogenet Genomics 22(12): 858-67
    › Primary publication · 23080225 (PubMed) · PMC3614365 (PubMed Central)
  8. The use of a DNA biobank linked to electronic medical records to characterize pharmacogenomic predictors of tacrolimus dose requirement in kidney transplant recipients. Birdwell KA, Grady B, Choi L, Xu H, Bian A, Denny JC, Jiang M, Vranic G, Basford M, Cowan JD, Richardson DM, Robinson MP, Ikizler TA, Ritchie MD, Stein CM, Haas DW (2012) Pharmacogenet Genomics 22(1): 32-42
    › Primary publication · 22108237 (PubMed) · PMC3237759 (PubMed Central)
  9. Toxicogenomics of nevirapine-associated cutaneous and hepatic adverse events among populations of African, Asian, and European descent. Yuan J, Guo S, Hall D, Cammett AM, Jayadev S, Distel M, Storfer S, Huang Z, Mootsikapun P, Ruxrungtham K, Podzamczer D, Haas DW, Nevirapine Toxicogenomics Study Team (2011) AIDS 25(10): 1271-80
    › Primary publication · 21505298 (PubMed) · PMC3387531 (PubMed Central)
  10. Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. Haas DW, Ribaudo HJ, Kim RB, Tierney C, Wilkinson GR, Gulick RM, Clifford DB, Hulgan T, Marzolini C, Acosta EP (2004) AIDS 18(18): 2391-400
    › Primary publication · 15622315 (PubMed)